Dr Thomas Brunner speaks to ecancer about the ESOPEC trial. This trial compared neoadjuvant chemoradiation (CROSS) to perioperative chemotherapy (FLOT) in oesophageal adenocarcinoma (EAC).

The findings show that the FLOT regimen is superior, leading to longer patient survival and better therapy tolerance.

The study emphasises the importance of FDG PET scans in treatment planning and suggests future use of FLOT while awaiting results from the Checkmate 577 trial on immune checkpoint inhibitors.